{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=22&state=Texas",
    "query": {
      "state": "Texas",
      "city": "Houston",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 22494,
    "total_pages": 2250,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=23&state=Texas&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=21&state=Texas&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T01:59:15.124Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01376778",
      "title": "A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Cytomegalovirus Infection",
        "Maternal Cytomegalovirus Infection"
      ],
      "interventions": [
        {
          "name": "CMV hyperimmune globulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The George Washington University Biostatistics Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 399,
      "start_date": "2012-04",
      "completion_date": "2021-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-11-05T01:59:15.124Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01376778"
    },
    {
      "nct_id": "NCT01073878",
      "title": "Athena Pelvic Muscle Trainer - DUETS Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Athena Pelvic Muscle Trainer",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Athena Feminine Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 70 Years · Female only"
      },
      "enrollment_count": 462,
      "start_date": "2010-02",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2011-07-14",
      "last_synced_at": "2026-11-05T01:59:15.124Z",
      "location_count": 96,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Casa Grande, Arizona + 87 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01073878"
    },
    {
      "nct_id": "NCT03701399",
      "title": "Troriluzole in Adult Participants With Spinocerebellar Ataxia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinocerebellar Ataxias",
        "Spinocerebellar Ataxia Type 1",
        "Spinocerebellar Ataxia Type 2",
        "Spinocerebellar Ataxia Type 3",
        "Spinocerebellar Ataxia Type 6",
        "Spinocerebellar Ataxia Type 7",
        "Spinocerebellar Ataxia Type 8",
        "Spinocerebellar Ataxia Type 10"
      ],
      "interventions": [
        {
          "name": "troriluzole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biohaven Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 299,
      "start_date": "2019-03-08",
      "completion_date": "2026-08",
      "has_results": true,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-11-05T01:59:15.124Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03701399"
    },
    {
      "nct_id": "NCT05892614",
      "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "efzofitimod 450 mg",
          "type": "DRUG"
        },
        {
          "name": "efzofitimod 270 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "aTyr Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2023-10-26",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2025-05-07",
      "last_synced_at": "2026-11-05T01:59:15.124Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • San Diego, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05892614"
    },
    {
      "nct_id": "NCT00901316",
      "title": "Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Community-Acquired Staphylococcus Aureus"
      ],
      "interventions": [
        {
          "name": "Routine Measures Group",
          "type": "PROCEDURE"
        },
        {
          "name": "Bleach Bath Group (Bleach plus routine measures)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Months to 18 Years"
      },
      "enrollment_count": 987,
      "start_date": "2009-06",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-11-05T01:59:15.124Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00901316"
    },
    {
      "nct_id": "NCT00856284",
      "title": "Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Alogliptin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Glipizide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 2639,
      "start_date": "2009-03",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2013-12-03",
      "last_synced_at": "2026-11-05T01:59:15.124Z",
      "location_count": 94,
      "location_summary": "Montgomery, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 91 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00856284"
    },
    {
      "nct_id": "NCT01050114",
      "title": "OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "onaBoNT-A",
          "type": "DRUG"
        },
        {
          "name": "Oxybutynin ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christopher Patrick Smith",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-08",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-30",
      "last_synced_at": "2026-11-05T01:59:15.124Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01050114"
    },
    {
      "nct_id": "NCT00003516",
      "title": "Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Antineoplaston therapy (Atengenal + Astugenal)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Burzynski Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "1996-03-27",
      "completion_date": "2004-03-18",
      "has_results": false,
      "last_update_posted_date": "2018-02-05",
      "last_synced_at": "2026-11-05T01:59:15.124Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003516"
    },
    {
      "nct_id": "NCT00242216",
      "title": "\"The Once A Day Protease Inhibitor Regimens\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ritonavir-boosted atazanavir",
          "type": "DRUG"
        },
        {
          "name": "ritonavir-boosted fosamprenavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2004-05",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2014-01-15",
      "last_synced_at": "2026-11-05T01:59:15.124Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00242216"
    },
    {
      "nct_id": "NCT01652716",
      "title": "Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Exenatide once weekly suspension",
          "type": "DRUG"
        },
        {
          "name": "Exenatide twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 377,
      "start_date": "2013-01",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2018-07-03",
      "last_synced_at": "2026-11-05T01:59:15.124Z",
      "location_count": 58,
      "location_summary": "Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01652716"
    }
  ]
}